Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 elacestrant monotherapy in Japanese patients with ER-positive/HER2-negative advanced or metastatic breast cancer with ESR1 mutation after CDK4/6 inhibitor therapy
jRCT2071260044Phase 2Recruiting
- Sponsor
- Stemline Therapeutics
- Start
- Aug 2026
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of elacestrant in breast cancer, sponsored by Stemline Therapeutics. Primary endpoint: IRC-assessed progression-free survival. Started Aug 2026; status: recruiting.
02
Drugs
elacestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2071260044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071260044.